Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary Tumor

Fudan University

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT06344767

YOUNGBC-27

Details and patient eligibility

About

To investigate the treatment pattern and efficacy of patients with negative primary ER lesion but positive ER expression in MBC using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).

Enrollment: 19 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with breast cancer (according to International Classification of Diseases 10th Revision) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a nonmetastatic stage.
• MBC patients who underwent 18F-FES PET/CT at the Fudan University Shanghai Cancer Center between 2012 and 2023
• Patients diagnosed with primary ER-negative tumor and who were yet to receive any systemic therapy during the advanced stage

Exclusion criteria

Patients with incomplete medical records and those diagnosed with secondary primary tumors

Trial design

19 participants in 1 patient group

FES positive in MBC

Description:

Patients who did not present with any ER-positive lesions in primary cancer were characterized as with any positive ER expression in the metastatic stage